| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/06/2007 | EP1792611A1 Matrix controlled transdermal system for stable derivatives of ACE inhibitors |
| 06/06/2007 | EP1792537A1 Method of constructing clone mammal |
| 06/06/2007 | EP1791870A1 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| 06/06/2007 | EP1791854A2 Methods of treating disorders having a component of mercury toxicity |
| 06/06/2007 | EP1613313B1 2-phenyl-benzimidazol and 2-phenyl-imidazo-4,5]-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer |
| 06/06/2007 | EP1489083B1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist |
| 06/06/2007 | EP1423389B1 Pyrazolo-pyridines for the treatment of herpes infections |
| 06/06/2007 | EP1406660B1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 06/06/2007 | EP1406637B1 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 06/06/2007 | EP1402034B1 Identification of ses-1 and the uses of the same |
| 06/06/2007 | EP1392254B1 Micellar drug delivery systems for hydrophobic drugs |
| 06/06/2007 | EP1381431B1 Aromatase inhibition to enhance implantation rate |
| 06/06/2007 | EP1363874B1 Tryptase inhibitors |
| 06/06/2007 | EP1289556B1 Isoflavones against radiation-induced mortality |
| 06/06/2007 | EP1011711B1 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors |
| 06/06/2007 | EP1009826B1 Erbb4 receptor-specific neuregulin, related ligands and uses thereof |
| 06/06/2007 | EP0982037B1 Use of tcf-ii for preventing or treating sepsis |
| 06/06/2007 | EP0886679B1 Parapoxviruses containing foreign dna, their production and their use in vaccines |
| 06/06/2007 | CN1976713A Citrus fruit skin extract for angiogenesis promotion |
| 06/06/2007 | CN1976691A Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 06/06/2007 | CN1974596A 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors |
| 06/06/2007 | CN1974574A Novel tricyclic spiropiperidines or spiropyrrolidines |
| 06/06/2007 | CN1973890A Medicine prepn for promoting intelligence growth and nourishing brain and its prepn process |
| 06/06/2007 | CN1973885A Shenjing capsule and shenjing oral liquid |
| 06/06/2007 | CN1973828A VEGF slowly releasing injection microsphere support and its prepn and use |
| 06/06/2007 | CN1319991C Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 06/06/2007 | CN1319975C Camptothecin analogs and methods of preparation thereof |
| 06/06/2007 | CN1319973C Piperidine derivatives |
| 06/06/2007 | CN1319968C Compositions useful as inhibitors of GSK-3 |
| 06/06/2007 | CN1319967C 2-acylaminothiazole derivative or salt thereof |
| 06/06/2007 | CN1319959C Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors |
| 06/06/2007 | CN1319958C Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 06/06/2007 | CN1319957C Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin |
| 06/06/2007 | CN1319950C 3-substituted-4-pyrimidone derivatives |
| 06/06/2007 | CN1319945C Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof |
| 06/06/2007 | CN1319593C Oral enteric-coated microsphere of Thymosin and preparation thereof |
| 06/06/2007 | CN1319548C Chinese medicine health tonic for raising antisenility capacity and improving memory |
| 06/06/2007 | CN1319534C Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
| 06/06/2007 | CN1319530C Neurotrophic factor production promoter |
| 06/06/2007 | CN1319528C Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure |
| 06/05/2007 | USRE39682 Enzyme inhibitors, for cancer therapy |
| 06/05/2007 | USRE39681 1-(4-sulfamyaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| 06/05/2007 | USRE39680 Sleep disorders associated with 5-HT2A serotonin receptor modulation; antagonists or agonists |
| 06/05/2007 | US7227022 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase |
| 06/05/2007 | US7227020 protein kinase inhibitors; asthma, psoriasis, antiinflammatory agents; inflammatory bowel disorders |
| 06/05/2007 | US7226945 Estrogen receptor-β ligands |
| 06/05/2007 | US7226938 Heterocyclic compounds |
| 06/05/2007 | US7226936 Pyridinic sulfonamide derivatives method of production and use thereof |
| 06/05/2007 | US7226929 drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents |
| 06/05/2007 | US7226921 An enzyme inhibitor of cysteine proteases, a morpholine-4-carboxyamide 1,3,4-oxadiazole derivatives; for treating arthritis, muscular dystrophy, inflammation, tumor, glomerulonephritis, malaria, periodontal disease |
| 06/05/2007 | US7226918 DNA-PK inhibitors |
| 06/05/2007 | US7226785 A single-stranded oligonucleotide with a DNA domain having at least one mismatch with respect to genetic sequence to be altered |
| 06/05/2007 | US7226757 Adding to the protein an aqueous solution of a charged polymer to reduce intermolecular or intramolecular interactions between positively and negatively charged domains; refolding |
| 06/05/2007 | US7226611 Glycosaminoglycan/collagen complexes and use thereof |
| 06/05/2007 | US7226587 To promote osteogenesis and therefore uses include fracture healing and repair and acceleration of fracture healing |
| 06/05/2007 | US7226586 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 06/05/2007 | US7226578 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis |
| 06/05/2007 | CA2385083C O-anisamide derivatives |
| 06/05/2007 | CA2376094C Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) .alpha. |
| 06/05/2007 | CA2356294C Pharmaceutical compositions for treating bone lesions in multiple myeloma |
| 06/05/2007 | CA2294385C Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 06/05/2007 | CA2293836C Polymorphic form of a tachykinin receptor antagonist |
| 06/05/2007 | CA2262847C Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
| 06/05/2007 | CA2237335C The use of cholinesterase inhibitors in the treatment of xerostomia |
| 06/05/2007 | CA2225528C Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues |
| 06/05/2007 | CA2157586C Indoletetralins having dopaminergic activity |
| 06/05/2007 | CA2143442C Dorsal tissue affecting factor and compositions |
| 06/05/2007 | CA2125644C Pharmaceutical compositions containing the salts of s(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids |
| 05/31/2007 | WO2007061130A1 Anti-tumor agent for multiple myeloma |
| 05/31/2007 | WO2007061127A1 Anti-tumor agent for multiple myeloma |
| 05/31/2007 | WO2007061074A1 Novel bisboron compound |
| 05/31/2007 | WO2007061022A1 Mitochondrial function of prohibitin 2 (phb2) |
| 05/31/2007 | WO2007060992A1 Agent for preventing or improving metabolic syndrome or insulin-resistance syndrome |
| 05/31/2007 | WO2007060974A1 Pharmaceutical for use in the treatment of ureterolithiasis |
| 05/31/2007 | WO2007060924A1 PROTECTING AGENT FOR PANCREATIC β-CELL |
| 05/31/2007 | WO2007060899A1 Application of actin-binding protein to disease associated with cell motility |
| 05/31/2007 | WO2007060802A1 Solid pharmaceutical preparation and pharmaceutical preparation composition |
| 05/31/2007 | WO2007060747A1 Galectin-9 induction factor |
| 05/31/2007 | WO2007059918A1 Use of a combination of ethynylestradiol and chlormadinone acetate for the treatment of mood changes |
| 05/31/2007 | WO2007037543A9 Biarylamide derivative |
| 05/31/2007 | WO2007037534A9 2-heteroaryl-substituted indole derivative |
| 05/31/2007 | WO2002094185A3 Conjugates and compositions for cellular delivery |
| 05/31/2007 | US20070124825 Use of hepcidin as a regulator of iron homeostasis |
| 05/31/2007 | US20070124083 Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| 05/31/2007 | US20070123706 Method for producing 3-amidinophenylalanine derivatives |
| 05/31/2007 | US20070123549 platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis |
| 05/31/2007 | US20070123532 Piperazine derivatives |
| 05/31/2007 | US20070123528 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 05/31/2007 | US20070123524 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; inhibitors of HIV replication; with other HIV/AIDS antivirals, anti-infectives, immunomodulators, antibiotics or vaccines; AIDS |
| 05/31/2007 | US20070123521 Cinnamoyl derivatives and use thereof |
| 05/31/2007 | US20070123503 Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| 05/31/2007 | US20070123459 IL-17 like molecules and uses thereof |
| 05/31/2007 | US20070123452 Method of selecting novel immunosuppressant |
| 05/31/2007 | US20070122493 Marine algae extract and glycosidase inhibitor containing the same |
| 05/31/2007 | US20070122451 Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food |
| 05/31/2007 | US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use |
| 05/31/2007 | US20070122394 administering a VEGFR modulating agent that comprises placental growth factor; a growth factor that binds and activates Flt-1 such as PIGF or VEGF-B, an anti-Flt-1 agonistic antibody or a small molecule agonist |
| 05/31/2007 | US20070122381 Method for regulating neuron development and maintenance |
| 05/31/2007 | US20070122367 Resorcinol derivatives |
| 05/31/2007 | US20070122348 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject |